Meet over 65 universities on 27 & 28 April GET YOUR FREE TICKET >
Anglia Ruskin University ARU Featured PhD Programmes
Anglia Ruskin University ARU Featured PhD Programmes

Does SUMO protease SENP3 play a role in α-synuclein aggregation and toxicity?


Department of Biomedical Science

About the Project

Pathogenic causes for progressive loss of dopaminergic neurons along with protein aggregates termed Lewy bodies in the substantia nigra in (SN) Parkinson’s disease (PD) are not yet understood. A protein called α-synuclein is the major component of the Lewy bodies. Familial mutations of α-synuclein lead to accelerated protein aggregation and cytotoxicity (1). Interestingly, α-synuclein undergoes a protein post-translational modification termed SUMOylation. It involves attaching the Small Ubiquitin MOdifier-like protein known as SUMO to the protein. Since SUMOylation is found to inhibit α-synuclein-mediated aggregation and cytotoxicity (2), to enhance SUMOylation levels may represent a promising therapeutic strategy against PD pathology. We have recently found that SUMO protease SENP3 negatively regulates SUMOylation levels via a process known as deSUMOylation where it detaches SUMO from SUMOylated proteins (3). This has led us to hypothesize that i) α-synuclein is a deSUMOylation substrate for SENP3, and (ii) SENP3-mediated deSUMOylation exacerbates PD neuropathies due to α-synuclein mutations. The findings from this project would better our understanding of molecular mechanisms underlying PD pathogenesis and identify new target(s) for future PD treatment.

The proposed work will directly test the hypothesis, and it will involve a combination of techniques, including those in molecular biology (e.g., cloning and tagging and site-directed mutagenesis), protein chemistry (e.g., glutathione S-transferase/Histidine pulldowns & co-immunoprecipitations followed by western blotting, protein purification and assays for SUMOylation/deSUMOyation), cell biology (e.g., cultures of clonal cell lines and neuronal cells, and DNA & sh/siRNA transfections/CRISPR-Cas9-mediated knockdown/knockout and replacement), together with In-cell quantitative analysis of the aggregation and the inclusion of α-synuclein under different SUMOylation statuses and biochemical examinations of cell viability (e.g., cytochrome c release, caspase activation, and MTT and LDH assays).

Science Graduate School
As a PhD student in one of the science departments at the University of Sheffield, you’ll be part of the Science Graduate School. You’ll get access to training opportunities designed to support your career development by helping you gain professional skills that are essential in all areas of science. You’ll be able to learn how to recognise good research and research behaviour, improve your communication abilities and experience the breadth of technologies that are used in academia, industry and many related careers. Visit http://www.sheffield.ac.uk/sgs to learn more.

Funding Notes

First class or upper second 2(i) in a relevant subject. To formally apply for a PhD, you must complete the University's application form using the following link: View Website

All applicants should ensure that both references are uploaded onto their application as a decision will be unable to be made without this information.

References

Reference
1. K. Rosborough, N. Patel, L. V. Kalia, alpha-Synuclein and Parkinsonism: Updates and Future Perspectives. Current neurology and neuroscience reports 17, 31 (2017).
2. P. Krumova et al., Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194, 49-60 (2011).
3. C. Guo et al., SENP3-mediated deSUMOylation of dynamin-related protein 1 promotes cell death following ischaemia. Embo j 32, 1514-1528 (2013).

Email Now

Insert previous message below for editing? 
You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need.
Why not add a message here

The information you submit to University of Sheffield will only be used by them or their data partners to deal with your enquiry, according to their privacy notice. For more information on how we use and store your data, please read our privacy statement.

* required field

Your enquiry has been emailed successfully





FindAPhD. Copyright 2005-2021
All rights reserved.